Immunisation rates for polio, chicken pox, tetanus and other diseases are significantly down from previous years since the government suspended the sale and distribution of the Dengvaxia vaccine in December, Health Undersecretary Enrique Domingo told reporters.
The government is also investigating Dengvaxia's alleged role in the deaths of at least 14 children who were among the 830,000 who got the vaccine as part of the world's first public dengue immunisation programme in 2016-2017.
The Philippine government is concerned about the potential for epidemics because of lower immunisation rates, he said.
Dengue -- a mosquito-borne disease -- infects 400 million people each year and kills 9,000 globally, the health department said, citing World Health Organisation data.
The Philippines has one of the highest dengue fatality rates in the world, with 732 deaths last year, it added.
The disclosure sparked nationwide panic, with some parents alleging the vaccine caused the deaths of their children.
"When you go to the communities, all the paediatricians are really heartbroken because all the patients -- the parents (and) the children -- feel that they are going to die," Domingo said.
Sanofi says no one has been proven to have died from the vaccine, but last month the French pharmaceutical giant agreed to reimburse the Philippine government for leftover doses.
"(Three children) died from dengue even though they were given Dengvaxia -- vaccine failure was the possible cause in two of them," the department said in a statement.
Nine others died of reasons unrelated to dengue, while the cause of two other deaths could not be determined.
Asked if the vaccine itself caused the three deaths, Juliet Sio-Aguilar, the head of the inquiry, told reporters on Friday that while it could be possible, "we cannot categorically say."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
